Q2 EPS Forecast for Puma Biotechnology Reduced by Analyst

Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) - Research analysts at Zacks Research cut their Q2 2025 EPS estimates for shares of Puma Biotechnology in a research report issued to clients and investors on Wednesday, April 30th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of $0.08 for the quarter, down from their prior forecast of $0.09. The consensus estimate for Puma Biotechnology's current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology's FY2025 earnings at $0.48 EPS, Q3 2026 earnings at $0.13 EPS and Q4 2026 earnings at $0.02 EPS.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The business had revenue of $59.10 million during the quarter, compared to the consensus estimate of $52.50 million.

A number of other equities research analysts have also commented on the company. StockNews.com lowered Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a research report on Saturday. HC Wainwright reaffirmed a "buy" rating and issued a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, February 28th.

Puma Biotechnology Stock Performance

Puma Biotechnology stock traded up $0.13 during trading hours on Friday, hitting $3.21. 327,172 shares of the stock traded hands, compared to its average volume of 442,280. The firm's 50 day moving average price is $3.13 and its 200-day moving average price is $3.04. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 1.40. The stock has a market capitalization of $159.32 million, a price-to-earnings ratio of 6.69 and a beta of 1.29. Puma Biotechnology has a 1 year low of $2.23 and a 1 year high of $5.20.

Hedge Funds Weigh In On Puma Biotechnology

A number of institutional investors have recently modified their holdings of PBYI. Acorn Capital Advisors LLC acquired a new stake in Puma Biotechnology during the fourth quarter worth about $7,475,000. American Century Companies Inc. grew its stake in shares of Puma Biotechnology by 8.4% during the 4th quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company's stock worth $2,893,000 after purchasing an additional 73,833 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Puma Biotechnology by 24.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company's stock valued at $2,635,000 after purchasing an additional 170,968 shares in the last quarter. Kennedy Capital Management LLC lifted its stake in shares of Puma Biotechnology by 36.5% in the 4th quarter. Kennedy Capital Management LLC now owns 809,375 shares of the biopharmaceutical company's stock valued at $2,469,000 after purchasing an additional 216,329 shares during the period. Finally, State Street Corp boosted its holdings in Puma Biotechnology by 17.0% during the third quarter. State Street Corp now owns 601,542 shares of the biopharmaceutical company's stock worth $1,534,000 after buying an additional 87,504 shares in the last quarter. Hedge funds and other institutional investors own 61.29% of the company's stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.